SLC5A2 and type 2 diabetes mellitus: Therefore, the present study was designed to evaluate the efficacy and safety profile of SGLT2 inhibitor empagliflozin with metformin in comparison with DPP4 inhibitor sitagliptin with metformin in terms of hypoglycemia, dehydration and glucose control in people with T2DM observing fast during Ramadan.